McLean Hospital/Harvard Medical School, Belmont, MA, United States of America.
Center for Anxiety, New York, NY, United States of America.
PLoS One. 2024 Mar 13;19(3):e0296949. doi: 10.1371/journal.pone.0296949. eCollection 2024.
The COVID-19 pandemic yielded a substantial increase in worldwide prevalence and severity of anxiety, but less is known about effects on anxiety treatment.
We evaluated effects of the COVID-19 pandemic on responses to Cognitive Behavioral Therapy for anxiety, in a clinically heterogeneous sample of patients.
A sample of 764 outpatients were separated into four groups: (1) Pre-pandemic (start date on or prior to 12/31/2019), (2) Pandemic-Onset (start date from 01/01/2020 to 03/31/2020), (3) During-Pandemic (start date from 04/01/2020 through 12/31/2020), and (4) Post-Pandemic (start date on or after 01/01/2021). We subsequently compared treatment trajectories and effects within and between these groups over 5621 total time points (mean of 7.38 measurements per patient).
Overall, patients presented with moderate levels of anxiety (M = 13.25, 95%CI: 12.87, 13.62), which rapidly decreased for 25 days (M = 9.46, 95%CI: 9.09, 9.83), and thereafter slowly declined into the mild symptom range over the remainder of the study period (M = 7.36, 95%CI: 6.81, 7.91), representing clinically as well as statistically significant change. A series of conditional multilevel regression models indicated that there were no substantive differences between groups, and no increase in anxiety during the acute pandemic phase.
Our results suggest that responses to treatment for anxiety were equivalent before, during, and after the COVID-19 pandemic. Among patients who were in treatment prior to the pandemic, we failed to detect an increase in anxiety during the pandemic's acute phase (March 20th, 2020 through July 1st, 2020).
COVID-19 大流行在全球范围内导致焦虑症的患病率和严重程度大幅上升,但对于其对焦虑症治疗的影响知之甚少。
我们评估了 COVID-19 大流行对接受认知行为疗法治疗焦虑症的患者的影响,这些患者具有临床异质性。
将 764 名门诊患者分为四组:(1)大流行前(开始日期为 2019 年 12 月 31 日或之前);(2)大流行开始时(开始日期为 2020 年 1 月 1 日至 2020 年 3 月 31 日);(3)大流行期间(开始日期为 2020 年 4 月 1 日至 2020 年 12 月 31 日);(4)大流行后(开始日期为 2021 年 1 月 1 日或之后)。随后,我们在 5621 个总时间点(每位患者平均 7.38 个测量值)内比较了这些组内和组间的治疗轨迹和效果。
总体而言,患者的焦虑症程度为中度(M=13.25,95%CI:12.87,13.62),焦虑症迅速下降了 25 天(M=9.46,95%CI:9.09,9.83),此后在研究期间的剩余时间里缓慢降至轻度症状范围(M=7.36,95%CI:6.81,7.91),这代表了临床和统计学上的显著变化。一系列条件多层回归模型表明,组间没有实质性差异,并且在急性大流行阶段焦虑没有增加。
我们的结果表明,COVID-19 大流行前后治疗焦虑症的反应相当。在大流行前接受治疗的患者中,我们未能检测到大流行急性阶段(2020 年 3 月 20 日至 2020 年 7 月 1 日)焦虑的增加。